Health ❯ Healthcare ❯ Clinical Trials ❯ Phase III Trials

OBERON and TITANIA Trials

AstraZeneca's Tozorakimab Cuts COPD Flare‑Ups in Two Phase 3 Trials

The drug showed broad benefit and a placebo‑like safety profile and now faces an expedited U.S. review with a PDUFA target in the first quarter of 2027.